Tendência de mortalidade por hepatites B e C no município de São Paulo, 2002–2016

Sato, Ana Paula Sayuri; Koizumi, Inês Kazue; Farias, Norma; Silva, Célia Regina Ciccolo da; Cardoso, Maria Regina Alves; Figueiredo, Gerusa Maria

doi:10.11606/s1518-8787.2020054002231

Cited by 13 publications

(10 citation statements)

References 27 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic hepatitis, especially hepatitis C, has a silent and asymptomatic evolution in most cases and is found in advanced stages of disease progression, when already with cirrhosis, fibrosis or hepatocellular carcinoma (BRASIL, 2018). In this study, among the variables related to hepatitis B, C and B+C, deaths were recorded, a value well below that found by Sato et al (2020) for the municipality of São Paulo (SP) from 2002 to 2016, where 540 deaths were recorded with hepatitis B as the underlying cause, 127 (23.52%) were due to acute infections and 413 were chronic infections (76.48%).…”

Section: Discussioncontrasting

confidence: 60%

Prevalence and mortality of hepatitis B e C in the state of Mato Grosso between 2011 and 2020

Benevenuto,

Santos,

De Oliveira

et al. 2024

CLCS

View full text Add to dashboard Cite

To evaluate the prevalence and cases of deaths from hepatitis B and C in the state of Mato Grosso between 2011 and 2020. This was an observational study of the ecological type with a quantitative and descriptive approach using secondary data obtained in health information systems from the state and municipalities of Mato Grosso between January 2011 and December 2020. Descriptive statistics and Pearson’s chi-square test were used, with a significance level of 5%. The study was approved by the Research Ethics Committee (CAAE: 19545619.1.0000.8088). A total of 6486 cases of hepatitis B, C and B+C were recorded, with 2012 being the year with the highest number of cases (12.47%) and 2020 the lowest (3.84%); there was a statistical significance between the number of cases of hepatitis in relation to the years. The prevalent etiological classification was hepatitis B (71.83%). Regarding deaths, there were 259 deaths, with the highest number recorded from 2014 to 2015 (12.74%) and 2011 the lowest number (5.02%). The category that caused the most deaths was chronic viral hepatitis, with more than half of the records (59.46%). There was statistical significance in the relationship between deaths and the years of study analyzed. This study showed that the results found are similar to other studies in other states and cities in Brazil that have a similar theme. Professionals and managers must take a critical look at prevention and health promotion actions for viral hepatitis B and C, primarily hepatitis B.

show abstract

Section: Discussioncontrasting

confidence: 60%

Prevalence and mortality of hepatitis B e C in the state of Mato Grosso between 2011 and 2020

Benevenuto,

Santos,

De Oliveira

et al. 2024

CLCS

View full text Add to dashboard Cite

show abstract

“…A high proportion of our participants had no prior exposure to Hepatitis B with only 9 out of every 100 participants having immunity due to Hepatitis B vaccination. Despite this, they had continued sexual exposure which increases the risk of acute infection in adults and is shown to contribute 23.5% of hepatitis related deaths [ 29 ]. These results are important for HIV prevention trials: firstly, HIV vaccine trial designs in the era of PrEP are opting for layering or combination designs in which HIV vaccine trial participants are either allowed to access oral PrEP or are actively given oral PrEP during the trial [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B status and associated factors among participants screened for simulated HIV vaccine efficacy trials in Kenya and Uganda

Mayanja

Rida²,

Kimani

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Introduction Hepatitis B (HBV) prevalence remains high in Sub Saharan Africa and among some key populations such as those with continued exposure through sexual contact. We assessed the HBV status among potential participants who were screened for simulated HIV vaccine efficacy trials in Kenya and Uganda. Methods We conducted a cross sectional analysis of data collected from individuals who were screened in Kenya (Nairobi) and Uganda (Entebbe and Kampala). The studies followed hypothetical procedures of an HIV vaccine efficacy trial and aimed to enroll HIV negative key and vulnerable populations at elevated risk of HIV acquisition. HBV status was the main outcome categorized using Hepatitis B surface antigen (HBsAg) and total Hepatitis B core antibody (HBcAb). Baseline characteristics potentially associated with never being infected were analyzed using logistic regression. Results We screened 1,366 participants with mean age (SD) 28.7 (7.3) years. Overall, 46.6% were from Entebbe, 50.7% had secondary or higher level of education, 76.4% had informal high-risk jobs and 56.3% were male. Kampala had only female participants contributing 60.6% of females screened. Of the screened participants, 94.7% and 3.4% were negative and positive for HBsAg respectively. The prevalence on HBV infection was 3.9% among males and 2.8% among females while prevalence by site was: Entebbe (4.9%); Kampala (4.1%) and Nairobi (0.3%). The highest HBV prevalence was found among participants aged 25-29-years (5.2%), those with primary level education (4.5%), and those in informal low risk jobs (6.5%). Considering 1265 participants with complete data on HBsAg and HBcAb-Total, HBV status was never infected (67.9%), past infection (28.5%), chronic infection (3.2%) and acute infection (0.5%). Of 859 who were never infected, 685 (79.7%) were tested for anti-HBs titers of whom 60 (8.8%) had titers >10IU/L (immune due to vaccination). The odds of never being HBV infected were lower among older individuals 25–29 years (AOR 0.51; 95%CI 0.36–0.71) and ≥30 years (AOR 0.35; 95% CI 0.25–0.49). The odds were higher among participants with informal high-risk jobs from Kampala (AOR 2.21; 95% CI 1.41–3.47) and Nairobi (AOR 2.61; 95% CI 1.72–4.00) compared to those from Entebbe. Conclusion HBV prevalence and immunity due to vaccination were low among HIV negative individuals who are eligible for HIV vaccine trials and prevalence varies by age, education level and main occupation. Younger individuals and those recruited from existing cohorts/ clinics have a higher likelihood of having no prior HBV infection. HIV prevention intervention trials are a platform to identify individuals that need HBV vaccination.

show abstract

“…No entanto, a prevalência de doenças hepáticas graves continua aumentando, pois existe um contingente de pessoas infectadas pelo VHB e pelo VHC em décadas passadas que desconhecem sua condição ou que foram diagnosticadas tardiamente, quando apresentaram sinais e sintomas de doença hepática grave, como cirrose e HCC, o que de mortalidade anual padronizada apresentou aumento e ultrapassou a mortalidade por aids, entre 1999 e 2007(LY et al, 2012). Sugere que a diminuição das taxas de mortalidade por hepatite B no Brasil possa ser atribuída em parte à vacinação, com diminuição da prevalência, mas também às medidas de prevenção contra a infecção pelo HIV iniciadas na década de 1980, como observado nos estudos de(GRIRNSVEN et al, 1989;ALTER et al, 1990: XIMENES et al, 2015 em outros países.Em relação à mortalidade por hepatite C,Sato et al (2020) verificaram uma tendência de redução de 4,79% ao anode 2009…”

unclassified

A Sífilis E a Sífilis Congênita No Cenário Atual: Uma Revisão Da Literatura

Fernandes¹,

Alexandre²,

Reinheimer³

2021

Medicina: Ciências Da Saúde E Pesquisa Interdisciplinar 4

View full text Add to dashboard Cite

show abstract

Tendência de mortalidade por hepatites B e C no município de São Paulo, 2002–2016

Cited by 13 publications

References 27 publications

Prevalence and mortality of hepatitis B e C in the state of Mato Grosso between 2011 and 2020

Prevalence and mortality of hepatitis B e C in the state of Mato Grosso between 2011 and 2020

Hepatitis B status and associated factors among participants screened for simulated HIV vaccine efficacy trials in Kenya and Uganda

A Sífilis E a Sífilis Congênita No Cenário Atual: Uma Revisão Da Literatura

Contact Info

Product

Resources

About